Item Number：C3471
-
Specification & Item NumberC3471-0020 (20ml)
-
Storage Conditions-20ºC
-
Conditions Carriagedry ice
-
Validity Period (Months)18
Product Introduction
MycoNator-2 is a member of the broad-spectrum tetracycline antibiotics, one of several semi-synthetic antibiotics available to prevent, treat and control contamination of cell lines by Mycoplasma species when used in tandem with MycoNator-1. The mode of action (MOA) of MycoNator -2 inhibits bacterial protein synthesis by blocking the attachment of transfer RNA-amino acid at the A-site on the 30S bacterial ribosome. More precisely they are inhibitors of the codon-anticodon interaction (i.e., the incoming aminoacyl-tRNAs to the A-site). Selectivity against bacterial versus eukaryotic ribosomes is due to both structural differences in the RNA of the ribosomal subunits and selective concentration in susceptible bacterial cells. MycoNator-2 offers treatment options when used sequentially and in combination with MycoNator-1 (a pleuromutilin antibiotic) to take advantage of the antibiotic synergism.
In human medicine, tetracyclines have been known since 1948 with the discovery of chlortetracycline and tetracycline from Streptomyces aureofaciens and oxytetracycline from S. rimosus. Minocycline was introduced in 1972. Although the lack of new versions of tetracycline reflects a declining role as the front-line therapy in many human infections, but on-going clinical development indicates continued interest in this polyketide antibiotic class. Tetracyclines were once considered broad-spectrum antibiotics but due to the relentless prevalence of bacterial resistance, among other things, these drugs have been reduced to niche indications. Although different classes of tetracyclines may see a revival, some of these newer drugs evade most tetracycline-resistant mechanisms and have a broad spectrum of activity.
In human medicine, tetracyclines have been known since 1948 with the discovery of chlortetracycline and tetracycline from Streptomyces aureofaciens and oxytetracycline from S. rimosus. Minocycline was introduced in 1972. Although the lack of new versions of tetracycline reflects a declining role as the front-line therapy in many human infections, but on-going clinical development indicates continued interest in this polyketide antibiotic class. Tetracyclines were once considered broad-spectrum antibiotics but due to the relentless prevalence of bacterial resistance, among other things, these drugs have been reduced to niche indications. Although different classes of tetracyclines may see a revival, some of these newer drugs evade most tetracycline-resistant mechanisms and have a broad spectrum of activity.
Product Application
MycoNator-2 is a member of the broad-spectrum tetracycline antibiotics, one of several semi-synthetic antibiotics available to prevent, treat and control contamination of cell lines by Mycoplasma species when used in tandem with MycoNator-1.
Production And Quality System
Manufacturing in accordance with cGMP guidelines, in accordance with ISO13485 production standards.
Download Product Related Materials
-
Online Message
-
-
Online consultation